Relmada Therapeutics
(NASDAQ) RLMD
Relmada Therapeutics Financials at a Glance
Market Cap
$672.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$58.88M
EPS (TTM)
-$1.11
P/E Ratio
-5.76
Dividend
$0.00
Beta (Volatility)
0.02 (Low)
Dividend
$0.00
Beta (Volatility)
0.02 (Low)
Price
$6.42
Volume
59,242
Open
$6.49
Price
$6.42
Volume
59,242
Open
$6.49
Previous Close
$6.42
Daily Range
$6.33 - $6.64
52-Week Range
$0.55 - $8.00
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.02 (Low)
Price
$6.42
Volume
59,242
Open
$6.49
Previous Close
$6.42
Daily Range
$6.33 - $6.64
52-Week Range
$0.55 - $8.00
Estimated Earnings Date
Aug 6, 2026
RLMD News
RLMD: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Relmada Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
17
CEO
Sergio Traversa, PhD, MBA
Website
www.relmada.comHeadquarters
Coral Gables, FL 33134, US
RLMD Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-71.22%
Return on Capital
-68.31%
Return on Assets
-25.02%
Earnings Yield
-17.36%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$672.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
104.89M
Volume
59.24K
Avg. Volume
1.60M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$60.34M
EBITDA
-$58.88M
Operating Cash Flow
-$42.79M
Capital Expenditure
$0.00
Free Cash Flow
-$42.79M
Cash & ST Invst.
$233.96M
Total Debt
$0.00
Relmada Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$672.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$39.55M
N/A
Employees
17
N/A
Net Income
-$19.05M
-8.5%
EBITDA
-$19.05M
-8.5%
Quarterly Fundamentals
Total Cash
$233.96M
+764.6%
Total Debt
$0.00
N/A
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-25.02%
N/A
Return on Invested Capital
-27.12%
N/A
Free Cash Flow
-$15.07M
+16.6%
Operating Cash Flow
-$15.07M
+16.6%